J&J’s new partnership with Elektrofi; Enyo raises €39M; Arrowhead’s $450M offering

Plus, news about TC BioPharm, BioCentriq, 4D Molecular and Arbor Biotechnologies, and Longboard Pharmaceuticals:

Johnson & Johnson teams up with Elektrofi: The Boston biotech will work with J&J’s Janssen Biotech to create an at-home self-administered under-the-skin version of a “lead oncology asset.” Elektrofi snagged an upfront payment of $18 million and could receive $155 million or more in milestones per target in the multi-target pact. — Kyle LaHucik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Sanofi Patent: Method for High-Level Expression of Multiple Target Polypeptides

Share this article According to GlobalData’s company profile on Sanofi, NSAID cancer drugs was a key innovation area identified from patents. Sanofi‘s grant share as

March 26, 2024

Opinion | Surgeon General: Vaping May Be an ‘Attractive’ Smoking Cessation Tool for Adults

Jeremy Faust is editor-in-chief of MedPage Today, an emergency medicine physician at Brigham and Women’s Hospital in Boston, and a public health researcher. He is

July 20, 2024

J&J’s Nisha Johnson on Ethizia wound-sealing patch, biosurgery market

Listen to the article 5 min This audio is auto-generated. Please let us know if you have feedback. Johnson & Johnson received a CE mark

May 28, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.